GARDEN CITY, N.Y. - Beyond Air, Inc. (NASDAQ: NASDAQ:XAIR), a medical device and biopharmaceutical company, has announced a strategic partnership with Healthcare Links, a healthcare advisory and contracting firm. The collaboration aims to enhance the distribution of Beyond Air’s LungFit® PH system by facilitating its entry into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) in the United States.
The LungFit® PH system is an innovative inhaled nitric oxide (NO) generator and delivery system designed to treat patients with persistent pulmonary hypertension of the newborn (PPHN) and other respiratory conditions. The system generates NO from ambient air, which could improve safety and operational efficiency by eliminating the need for cylinder storage.
Ken Murawski, President of Healthcare Links, expressed enthusiasm about introducing the LungFit PH system to their network, citing its potential to transform patient care and enhance healthcare provider logistics. Steve Lisi, Chairman and CEO of Beyond Air, emphasized the partnership's role in scaling access to their NO delivery technology for hospitals.
The LungFit® PH system has been cleared for commercial use in the U.S. for treating term and near-term neonates with hypoxic respiratory failure. Beyond Air and Healthcare Links are committed to simplifying the contracting process, aiming to make the advanced respiratory therapy more readily available across the country.
Beyond Air’s LungFit platform, recognized as a medical device by the FDA, is designed to address a variety of respiratory conditions, potentially replacing large NO cylinders in hospitals and facilitating treatment at home. The company also explores NO’s role in treating severe lung infections and its antimicrobial properties against a range of pathogens.
This press release contains forward-looking statements about Beyond Air’s expectations regarding the partnership's impact on market access and the potential benefits of the LungFit® PH system. However, these statements are subject to inherent risks and uncertainties that could cause actual results to differ materially from those anticipated.
The information in this article is based on a press release statement from Beyond Air, Inc.
In other recent news, Beyond Air has made significant strides in both its clinical and financial sectors. The medical device and biopharmaceutical company deployed its LungFit® PH system at the U.S. Naval Hospital Guam, a move that aims to enhance the hospital's neonatal critical care capabilities. The FDA-approved system, designed for treating newborns with persistent pulmonary hypertension, is expected to improve patient outcomes and expand the use of nitric oxide therapy in critical care.
Beyond Air also announced its financial restructuring, retiring a $17.5 million debt with Avenue Capital and establishing a new $11.5 million loan agreement. This move eliminates $12 million in scheduled debt payments through mid-2026, and is expected to support the company's operations until the same timeframe. Despite withdrawing its revenue guidance for the fiscal year 2025, Beyond Air remains optimistic about the commercial prospects of LungFit PH.
In terms of analyst notes, Roth/MKM upgraded Beyond Air's stock to a 'Buy' rating, citing the potential of the LungFit PH system. However, Piper Sandler reduced its price target for Beyond Air shares to $1.00 while maintaining an Overweight rating. For the first quarter, Beyond Air reported revenue of $0.6 million and an operating loss of $13.5 million. Despite these figures, the company adjusted its fiscal year 2025 revenue outlook, now expecting to exceed $10 million. These are the recent developments in Beyond Air's journey.
InvestingPro Insights
Beyond Air's strategic partnership with Healthcare Links comes at a critical time for the company, as reflected in recent financial data and market trends. According to InvestingPro data, Beyond Air's market capitalization stands at a modest $14.04 million, with its stock price trading near its 52-week low. This partnership could be crucial for the company's growth trajectory, especially considering that analysts anticipate sales growth in the current year, as highlighted by one of the InvestingPro Tips.
The company's financial health presents a mixed picture. On one hand, Beyond Air holds more cash than debt on its balance sheet, and its liquid assets exceed short-term obligations, providing some financial stability. However, the company is not currently profitable, with a negative P/E ratio of -0.19. This aligns with another InvestingPro Tip indicating that Beyond Air is quickly burning through cash, which underscores the importance of successful commercialization of the LungFit® PH system.
Despite these challenges, there are positive signals for investors to consider. Net income is expected to grow this year, and analysts predict the company will be profitable this year, according to InvestingPro Tips. These projections suggest that the partnership with Healthcare Links and the potential wider adoption of the LungFit® PH system could significantly impact Beyond Air's financial performance.
It's worth noting that Beyond Air's stock has experienced significant volatility, with a 31.7% decline in the past month and an 85.83% drop over the past year. This volatility, combined with the company's innovative technology and strategic partnerships, presents a complex picture for investors to evaluate.
For those seeking a more comprehensive analysis, InvestingPro offers 16 additional tips on Beyond Air, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.